Video
Dr. Davids on Ibrutinib Plus FCR in Younger Patients With CLL
Author(s):
In Partnership With:
Matthew S. Davids, MD, MMSc, Associate Director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib plus FCR in younger patients with CLL.
Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib (Imbruiva) plus fludarabine-cyclophosphamide-rituximab (FCR) in younger patients with chronic lymphocytic leukemia (CLL).
In a study of patients aged 65 or less, ibrutinib is being combined with FCR for up to 6 months, followed by ibrutinib maintenance therapy.
Davids says that many patients in this population like the idea of a combinatorial time-limited approach to treatment, and since they are a fit population, they can undergo a more intensive therapeutic regimen.
